Vir Biotechnology (VIR) Receivables (2020 - 2022)

Vir Biotechnology (VIR) reported Receivables of $7.0 million for Q2 2022, down 99.43% sequentially from $1.2 billion in Q1 2022.

Vir Biotechnology (VIR) Receivables (2020 - 2022) Analysis & Trends

Vir Biotechnology (VIR) has 3 years of Receivables data on file, last reported at $7.0 million in Q2 2022.

For the quarter ending Q2 2022, Receivables changed N/A year-over-year to $7.0 million; the trailing twelve-month figure through Jun 2022 stood at $7.0 million (changed N/A YoY), and the FY2021 full-year result was $773.1 million, changed N/A from the prior year.
Receivables declined to $7.0 million in Q2 2022, from $1.2 billion in the prior quarter.
In the past five years, Receivables ranged from a high of $1.2 billion in Q1 2022 to a low of $3.8 million in Q2 2020.
A 3-year average of $387.5 million and a median of $159.0 million in 2021 frame the typical range for Receivables.
Peak annual rise in Receivables reached 443.63% in 2022, while the deepest fall reached 443.63% in 2022.
Tracing VIR's Receivables over 3 years: stood at $3.8 million in 2020, then jumped by 20244.18% to $773.1 million in 2021, then sank by 99.09% to $7.0 million in 2022.
Business Quant data shows VIR's Receivables at $7.0 million in Q2 2022, $1.2 billion in Q1 2022, and $773.1 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Vir Biotechnology	1.38 Bn	1.38 Bn	-	-

Download Data